Tarsier Pharma Ltd. (TARX)
Tarsier Pharma will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
Tarsier Pharma is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet need in blinding diseases of the eye with underlying inflammatory pathologies.
Our dazdotuftide platform technology is a bio-inspired immunomodulator, designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops (TRS01) and intravitreal injections (TRS02).
Tarsier Pharma Ltd.
| Country | Israel |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Daphne Haim-Langford, Ph.D. |
Contact Details
Address: 10 HaMa’apilim St. Zichron Yaacov, 3093765 Israel | |
| Phone | +972-4-639-8050 |
| Website | tarsierpharma.com |
Stock Details
| Ticker Symbol | TARX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002102720 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daphne Haim-Langford, Ph.D. | Chief Executive Officer and Chairperson of the Board |
| Arie Ganot, CPA | Chief Financial Officer |
| Zohar Milman, M.Sc. | Chief Operating Officer |
| Ron Neumann, M.D. | Chief Medical Officer |
| Susan Benton | Director |
| Sascha Bucher | Director |
| Atul Raut | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Mar 31, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 24, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 29, 2025 | DRS | [Cover] Draft Registration Statement |